EUVIMEDEUVIMED entdecken
Open Access

Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy

Yaron Gu, Sophy T F Shih, Nimeshan Geevasinga, Linda Chan, John W Frew, Deshan F Sebaratnam

JAMA Dermatology · 01.06.2024 · 160 (6) · 631

DOI: 10.1001/jamadermatol.2024.1037 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA Dermatology, erschienen am 01.06.2024. Verfasst von Yaron Gu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia. Hauptthemen laut MEDLINE: Anticonvulsants, Asian People, Carbamazepine, Cost-Benefit Analysis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The HLA-B*15:02 allele has been associated with an increased risk of carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in specific Asian populations (including Han Chinese, Malaysian, Thai, and Vietnamese individuals). While HLA-B*15:02 genotype testing in Asian populations is recommended by several international prescribing guidelines, it is not subsidized by the Medicare Benefits Schedule in Australia.

Objective

To evaluate the cost-effectiveness of HLA-B*15:02 genotyping in Asian Australian patients with epilepsy. Design, Setting, and Participants A model with components of decision analysis and Markov simulation was developed to simulate clinical trajectories of adult Asian Australian patients with newly diagnosed epilepsy being considered for carbamazepine treatment. Cost-effectiveness and cost-utility analyses over a lifetime time horizon were conducted from the perspective of the Australian health care sector. The study was conducted in May 2023 and data analysis was performed from August 2023 to November 2023.

Intervention

No HLA-B*15:02 genotyping and the empirical initiation of treatment with carbamazepine vs HLA-B*15:02 genotyping and the initiation of treatment with valproate in allele carriers. Main Outcomes and Measures Life-years (LYs), quality-adjusted life-years (QALYs), and costs in 2023 Australian dollars (A$); incremental cost-effectiveness ratios.

Results

HLA-B*15:02 screening was associated with an additional mean cost of A$114 (95% CI, −A$83 to A$374; US$76; 95% CI, −US$55 to US$248) and a reduction in 0.0152 LYs (95% CI, 0.0045 to 0.0287 LYs) but improvement by 0.00722 QALYs (95% CI, −0.0247 to −0.01210) compared with no screening, resulting in an incremental cost-effectiveness ratio of A$15 839 per QALY gained (US$10 523 per QALY). Therefore, universal genotyping for Asian Australian individuals was cost-effective compared with current standards of practice at the A$50 000 per QALY willingness-to-pay threshold. Sensitivity analyses demonstrated that the intervention remained cost-effective across a range of costs, utilities, transition probabilities, and willingness-to-pay thresholds. At the A$50 000 per QALY willingness-to-pay threshold, universal screening was the preferred strategy in 88.60% of simulations. Conclusions and Relevance The results of this economic evaluation suggest that HLA-B*15:02 screening represents a cost-effective choice for Asian Australian patients with epilepsy who are being considered for treatment with carbamazepine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsAsian PeopleCarbamazepineCost-Benefit AnalysisEpilepsyHLA-B15 AntigenAdultFemaleHumansMaleMiddle AgedAustraliaGenotypeQuality-Adjusted Life YearsStevens-Johnson SyndromeAustralasian People

Substanzen

AnticonvulsantsCarbamazepineHLA-B*15:02 antigenHLA-B15 Antigen

Autor:innen und Institutionen

  • Faculty of Medicine and Health, University of New South Wales, Kensington, New South Wales, Australia.
  • Department of Dermatology, Liverpool Hospital, Liverpool, New South Wales, Australia.
  • The Kirby Institute, University of New South Wales Medicine and Health, Sydney, New South Wales, Australia.
  • School of Medicine, Western Clinical School, University of Sydney, Sydney, New South Wales, Australia.
  • Department of Dermatology, Westmead Hospital, Westmead, New South Wales, Australia.
  • Laboratory of Translational Cutaneous Medicine, Ingham Institute of Applied Medical Research, Liverpool, New South Wales, Australia.

Zitieren

APA

Gu, Y., Shih, S. T. F., Geevasinga, N., Chan, L., Frew, J. W., & Sebaratnam, D. F. (2024). Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy. JAMA Dermatology, 160(6), 631. https://doi.org/10.1001/jamadermatol.2024.1037

Vancouver

Gu Y, Shih STF, Geevasinga N, Chan L, Frew JW, Sebaratnam DF. Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy. JAMA Dermatology. 2024;160(6):631. doi:10.1001/jamadermatol.2024.1037

BibTeX
@article{Gu2024,
  author = {Gu, Yaron and Shih, Sophy T F and Geevasinga, Nimeshan and Chan, Linda and Frew, John W and Sebaratnam, Deshan F},
  title = {Economic Evaluation of HLA-B*15:02 Genotyping for Asian Australian Patients With Epilepsy},
  journal = {JAMA Dermatology},
  year = {2024},
  volume = {160},
  number = {6},
  pages = {631},
  doi = {10.1001/jamadermatol.2024.1037}
}
Kostenlos starten →